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 Abstract 
Effective control of Mycobacterium tuberculosis is a global necessity. In 2015, tuberculosis (TB) 
caused more deaths than HIV. Considering the increasing prevalence of multi-drug resistant forms of 
M. tuberculosis, the need for effective TB vaccines is imperative. Currently, the only licensed TB 
vaccine is Bacillus Calmette-Guérin (BCG). Yet, BCG has many drawbacks limiting its efficacy and 
applicability. We applied advanced computational procedures to derive a universal TB vaccine and 
one targeting East Africa. Our approach selects an optimal set of highly conserved, experimentally 
validated epitopes, with high projected population coverage (PPC). Through rigorous data analysis, 
five different potential vaccine combinations were selected each with PPC above 80% for East Africa 
and above 90% for the World. Two potential vaccines only contained CD8+ epitopes, while the 
others included both CD4+ and CD8+ epitopes. Our prime vaccine candidate was a putative seven-
epitope ensemble comprising: SRGWSLIKSVRLGNA, KPRIITLTMNPALDI, AAHKGLMNIALAISA, 
FPAGGSTGSL, MLLAVTVSL, QSSFYSDW and KMRCGAPRY, with a 97.4% global PPC and a 92.7% East 
African PPC.  
  
1. INTRODUCTION 
Mycobacterium tuberculosis infects populations worldwide. Due in part to troubling rates of new 
and relapsing tuberculosis (TB), the estimated 2015 death toll from TB was 1.8 million, with 10.5 
million new cases recorded (1). Mortality rates are disproportionately high in Africa (2): for example, 
in 2015, Kenya was reported to have TB affecting over 81,000 people and causing the deaths of at 
least 16,000 people. TB usually presents as a pulmonary disease transmitted by droplet inhalation 
resulting in symptoms such as persistent cough, fever, and night sweats (3). Individuals with healthy 
immune systems can often suppress the disease, typically being asymptomatic but with a latent 
infection. Problems arise for immunocompromised patients who cannot mount an immune response 
sufficient for the suppression of symptoms.  
The M. tuberculosis genome comprises over 4 million base pairs and approximately 4,000 genes (4). 
The immune response mounted against M. tuberculosis mainly involves cellular immunity, including 
CD4+ and CD8+ T cells (5, 6). Once activated, both CD4+ and CD8+ T cells secrete cytokines inducing 
an immune response. The CD8+ cells also mediate cytotoxicity and lysis of infected cells. Effective T 
cell responses are essential for M. tuberculosis elimination 
The slow growth rate of M. tuberculosis (792-932 minute doubling time), its complex pathogenesis, 
and its capacity to remain dormant, are major challenges to the development of effective 
treatments against TB (7). This is compounded by widespread resistance to antibiotics, such as 
isoniazid and rifampicin, with 480,000 cases of multi-drug resistant TB emerging annually (8). Thus, 
vaccination against TB remains a priority; especially in the developing world, particularly many 
African countries, India, and Indonesia, where the disease is widespread (1).  
The Bacillus Calmette-Guérin (BCG) vaccine - the only currently available TB vaccine offering 
prophylaxis - is an attenuated form of Mycobacterium bovis, used globally since 1923. Estimates 
suggest over 3 billion people have been vaccinated with BCG (9). BCG has subsequently come under 
much scrutiny. Each BCG vaccine dose, whilst containing a preparation of attenuated M. bovis, has 
different biological effects, as the amount of viable versus dead organisms in each dose varies (10). 
Depending on the strain used, immunogenicity, reactogenicity and viability varies by manufacturer. 
BCG has efficacy ranging from 0 to 80% against adult pulmonary TB (10, 11), providing protection for 
10 to 20 years from immunisation. As a partially-effective vaccine, BCG only protects paediatric 
patients from severe TB. BCG, as a live-attenuated vaccine, is seen as having a low safety profile due 
to the risks associated with its use in immunocompromised people and the possibility of the 
bacterium reverting to its virulent form (12). BCG’s varying efficacy is a particular problem in 
developing countries, such as East Africa. The need for effective, safe TB vaccines is clear.  
Sixteen TB vaccine candidates are currently in phase I, II, and III (13). Almost half of these candidate 
vaccines contain a live attenuated form of M. tuberculosis. Such an approach comes with many 
safety concerns. Indeed, BCG is contraindicated in patients with human immunodeficiency virus 
(HIV). Immunocompromised people are at increased risk of disseminated BCG disease (1). 
Disseminated BCG disease is a rare, life-threatening complication presenting with symptoms such as 
persistent fever, infection, weight loss and night sweats (14).  
Viral vector-based vaccines include recombinant Vaccinia strain Ankara virus (MVA), synthesised to 
express antigen 85A of M. tuberculosis and an adenovirus expressing the mycobacterial antigens 
85A, 85B and TB10.4 known as the Crucell-Ad35/AERAS-402 vaccine (15). However, previous 
exposure to the vector can reduce vaccine efficacy. Prophylactic live vaccines are also being 
developed, such as recombinant BCG VPM1002 and MTBVAC (5, 6). Live vaccines can revert to a 
pathogenic form. This is particularly dangerous for immunocompromised individuals. Inoculating 
patients with subunit-based vaccines eliminates risks of reversion to virulence. Subunit vaccines 
include the H1 vaccine which combines 85B and ESAT-6 antigens, H4 which combines antigens 85B 
and TB10.4 and M72 combining antigens 39A and 32A. However, subunit vaccines lack intrinsic 
immunogenicity, and are seldom able to induce long-term immunity against diseases, necessitating 
multiple vaccinations and the inclusion of adjuvants.  
The Phase I trial of AERAS-422, a recombinant BCG vaccine, studies, were discontinued when two 
participants developed the Varicella-Zoster virus (16). M72/AS01E is a candidate subunit vaccine 
initially deemed clinical safe in both healthy and TB-infected adults. However, during Stage II trials, 
many volunteers suffered local reactions at injection sites ending the study prematurely (17). 
Another subunit vaccine, MVA85A, initially looked promising. Proposed as an adjunct to 
conventional BCG vaccination, it showed effective protection in animal models. Unfortunately, 
MVA85A did not show similar efficacy in healthy infants and adults (18).  
Given the success of peptide subunit vaccine candidates such as H4/IC31, peptide vaccines should be 
considered strong potential TB vaccines. H4/IC31 had clinically safe profiles in Phase I trials inducing 
a positive immune response in healthy adults and infants already vaccinated with BCG (19). Peptide 
vaccines can be freeze-dried maintaining stability without a cold-chain (20). Apart from low 
manufacturing costs (21), peptide vaccines typically also have higher safety profiles, due to the use 
of epitopes without reactogenic responses (20).  
In this work we sought to design an anti-TB epitope ensemble vaccine applying an emerging 
approach in computational vaccinology. An ideal vaccine would concentrate on highly conserved 
immunogenic epitopes with a wide population coverage. We have recently begun to exemplify the 
approach by identifying epitope ensemble vaccine against Hepatitis C (22), influenza (23), and 
malaria (24). Likewise, here we selected M. tuberculosis epitopes of proven immunogenicity that can 
be combined to form an effective, widely-applicable epitope ensemble vaccine, defining both a 
global vaccine and one focussing on East Africa. 
 2. METHODS 
2.1. Collection of Mycobacterium tuberculosis-Specific Epitopes 
The Immune Epitope Database and Analysis Resource (IEDB; URL: http://www.iedb.org/) (25, 26) 
was used to collect M. tuberculosis-specific epitopes. Epitope search terms: any disease, antigen ID: 
Mycobacterium tuberculosis 1773, human host, and positive T cell assays. MHC Class I and II data 
were collected separately. The number of MHC I and MHC II epitopes were narrowed by selecting 
antigens with four or more epitopes (CD8+, Class I) or fifteen or more epitopes (CD4+, MHC Class II).  
2.2 Protein Sequences and Multiple Sequence Alignments 
Protein sequences of selected antigens were retrieved from the NCBI (National Centre for 
Biotechnology Information; http://www.ncbi.nlm.nih.gov/). For replaced or removed sequences, the 
most recently updated sequence was used. The retrieved antigen sequences were run against the 
NCBI Reference Proteins (RefSeq) database using automated BLASTP (27), with maximum hit 
sequences limited to 100 and restricting the search to Mycobacterium tuberculosis. Multiple 
Sequence Alignments (MSAs) were generated using COBALT (28).  
2.3. Analysis of Epitope Sequence Variability  
Conserved epitopes were identified by determining variable versus conserved sequence positions by 
analysing each separate MSA using the Protein Variability Server, PVS hereafter (29) (URL: 
http://imed.med.ucm.es/PVS/). Sequence variability was masked and only fragments with a length 
greater or equal to 9 were selected. The Shannon entropy threshold was set to 0.5.  
2.4. Prediction of HLA binding profile for Conserved Epitopes   
IEDB was used to calculate the binding profiles of MHC Class I (http://tools.iedb.org/mhci/) and Class 
II (http://tools.iedb.org/mhcii/) highly conserved epitopes. HLA I reference set was used for MHC I 
epitopes (30) and an HLA II reference set was used for MHC II epitopes (31). For MHC Class I, 
epitopes were chosen with a percentile rank less than or equal to one. For MHC Class II, epitopes 
with a percentile rank greater than or equal to five were omitted.  
2.5. Calculation of Projected Population Coverage (PPC) and Optimal Epitope Identification 
The PPC of highly conserved epitopes were calculated using IEDB 
(http://tools.iedb.org/tools/population/iedb_input). MHC I and MHC II epitopes were then ranked 
by PPC. Epitopes were combined within each class to calculate PPC’s for the World and East Africa. 
MHC I and II epitopes were also combined and the PPC calculated. Vaccine combinations were 
ranked by PPC’s in descending order with criteria of 90% or higher for the world and 80% or higher 
for East Africa.      
 3. RESULTS 
3.1 MHC Class I Epitope selection and combination 
Using IEDB, a total of 400 epitopes were obtained from 122 different TB antigens. Following Damfo, 
Reche (24), we focussed on epitope-rich antigens containing four or more epitopes: 18 different 
antigens were identified containing a total of 259 epitopes (Figure 1A). Of these, 151 were 
conserved, as determined by PVS (29).  The binding profile and percentage population coverage of 
each epitope was calculated using IEDB. Epitopes were selected on the allele diversity of their 
binding profiles and a PPC of at least 20% for the World or East Africa (Table 1).  
By choosing the epitope with the highest global PPC (MLLAVTVSL) and then selecting epitopes that 
bound different HLA I alleles, PPC values for epitope combinations were calculated. Combining MHC 
I epitopes - QSSFYSDW, ALAALGLWLSV, MLLAVTVSL, AEQEQCLDEL, FPAGGSTGSL, HISSGVFLLK, 
KMRCGAPRY, WYYQSGLSI, NTPAFEWYY - gave a maximum PPC of 97.8% for the World and 86.1% for 
East Africa. A comparable combination - QSSFYSDW, MLLAVTVSL, AEQEQCLDEL, FPAGGSTGSL, 
HISSGVFLLK, KMRCGAPRY, WYYQSGLSI - gave a PPC of 97.1% for the World and 85.6% for East 
Africa.  
 
3.2 MHC Class II Epitope selection and combination 
Using IEDB, a total of 1007 epitopes were obtained from 325 different TB antigens. By focussing on 
antigens with fifteen or more epitopes, 15 different antigens were identified. (Figure 1B). Of the 
resulting 381 epitopes, 239 were conserved, as determined using PVS. The binding profile and 
percentage population coverage of each epitope was calculated using IEDB. Epitopes were selected 
on the allele diversity of their binding profiles and a PPC of at least 20% for the World or East Africa 
(Table 2).   
By choosing the epitope with the highest global PPC (KPRIITLTMNPALDI) and then selecting epitopes 
that bound different HLA I alleles, PPC values for epitope combinations were calculated. The MHC II 
epitope combination comprising SRGWSLIKSVRLGNA, KPRIITLTMNPALDI and AAHKGLMNIALAISA 
gave a PPC of 81.8% for the World and 68.3% for East Africa.  
 
3.3 MHC I and II Combined  
To increase the overall PPC values, and achieve PPC over 75% in East Africa and 85% globally, MHC I 
and II epitopes were combined (Table 3). All combinations contained the final set of MHC II epitopes. 
Given the constraint of providing the greatest projected population coverage with the minimum 
number of epitopes, we did not combine all MHC I and MHC II epitopes. Effective PPC’s were 
considered to have greater than 90% coverage for the World and greater than 80% coverage for East 
Africa (Table 3). 
 
3.4 Cross-reactivity with the Human Proteome 
As a surrogate for potentially dangerous auto-immune reaction, mediated by epitope cross-
reactivity with the human proteome, we compared the sequences of the final epitope selection 
comprising the highest scoring vaccine with BLASTP, which automatically adjusts for short sequence 
lengths. The results - SRGWSLIKSVRLGNA [best overlap: 60%; % identity: 64%; best match: 
AAK97224.1], KPRIITLTMNPALDI [60%; 78%; BAF94735.1], AAHKGLMNIALAISA [46%; 100%; 
EAW74100.1], FPAGGSTGSL [80%; 100%; XP_016857235.1], MLLAVTVSL [100%; 89%; EAW77954.1], 
QSSFYSDW [75%; 100%; XP_016863485.1], KMRCGAPRY [66%; 100%; CAC51389.1] – indicate, at 
best, poor partial matches to a variety of human proteins.   
 
 
 
 4. DISCUSSION 
We have sought to define a putative epitope ensemble vaccine selecting epitopes of known 
immunogenicity to optimise predicted population coverage. Although the BCG vaccine has been 
used for many years, it has a varying efficacy especially in adults presenting with pulmonary TB. A 
viable TB vaccine should have high specificity with universal coverage to reduce the rate of disease-
associated illness and death. Our aim was to identify combinations of conserved epitopes able to 
stimulate appropriate, desirable immune responses against M. tuberculosis. We generated a number 
of essentially equivalent combinations of class I and class II epitopes to yield a PPC above 90% 
(universal or world vaccine) and above 80% for an East Africa-specific vaccine. The best MHC II 
epitope combination gave a maximum PPC lower than expected, although typically MHC II epitopes 
have a greater range of HLA binding profiles and should thus have higher PPC values.  
Vaccines should induce immune responses of a quality and strength sufficient to induce effective 
protection (32) without immune-mediated adverse reactions, such as anaphylaxis. Peptide vaccines 
can do this by using an optimal number of epitopes: the fewer the epitopes used, the less likely 
negative immunogenicity. Moreover, potential adverse reactions may also be mitigated by focussing 
the immune response to a restricted set of antigens, since side reactions can likewise be minimised.  
Of the twelve epitopes that made it into the final combinations of potential vaccines, six 
(KPRIITLTMNPALDI, SRGWSLIKSVRLGNA, AEQEQCLDEL, FPAGGSTGSL, HISSGVFLLK and KMRCGAPRY) 
come from phosphofructokinase PfkB, an essential gene in TB, a vital enzyme in carbohydrate 
metabolism. It has low similarity to host sequences, reducing the risk of auto-immunity (33). Two of 
the final epitopes – ALAALGLWLSV and MLLAVTVSL - come from the gene Rv1733c, often described 
as a latent antigen. It produces a high T cell response in latently infected patients and is highly 
expressed by dormant versions of the bacterium.  
Epitopes WYYQSGLSI and NTPAFEWYY arise from the M. tuberculosis gene fbpB, involved in the 
maintenance of the Mycobacterial cell wall (34). They originate from the secreted antigen 85-B, 
present during early infection. Also known as Rv1886c, antigen 85-B has long been viewed as a 
potential subunit vaccine candidate (35). Expression of Ag85-B is greater than that of its 
counterparts Ag85-A and Ag85-C, being a key secreted proteins of M. tuberculosis (36). QSSFYSDW 
derives from antigen 85-A, which is currently undergoing clinical trials as a candidate subunit vaccine 
(37). The MHC Class II epitope AAHKGLMNIALAISA, derives from a phosphate-binding protein which 
can stimulate CD4+ T cells, leading to production of IFN-γ, IL-22 and IL-17 (38).  
In terms of HLA I diversity versus pathogen-prevalence, African populations have greater HLA 
diversity (39). Sub-Saharan Africa is the most genetically-diverse population in the world. (40) 
studied the commonest HLA I alleles in the East Africa: HLA-A*01:01, HLA-A*02:01, HLA-A*03:01, 
HLA-A*23:01, HLA-A*30:02, HLA-B*07:02, HLA-B*08:01, HLA-B*35:01, HLA-B*44:03, HLA-B*51:01, 
HLA-B*53:01, HLA-B*57:01 and HLA-B*58:01 cover 80 to 90% of the East African population. All 
these alleles are found in our final epitope combinations. The FPAGGSTGSL MHC I epitope, with an 
East African PPC value of 33.6%, binds to all the common alleles in East Africa. The same applies for 
the QSSFYSDW epitope which has the highest East African population coverage (34.1%).  
Dunand, Ng (41) highlights the genetic differences between black East Africans and other African 
populations, suggesting the need to create a TB vaccine specifically targeting East African. Of the 
HLA II genes, the HLA-DRB1 alleles exhibits the highest polymorphism (41). Chen et al. (2015) have 
shown this allele to have a likely protective role against M. tuberculosis. Dunand et al. (1997) 
showed HLA-DRB1*11:01 occurs frequently in the Kenyan population. The three MHC II epitopes 
used in the final vaccine combinations (SRGWSLIKSVRLGNA, KPRIITLTMNPALDI and 
AAHKGLMNIALAISA), all bind this allele leading to high East African PPC values. 
The final vaccine combinations typically had higher predicted population coverages for the World 
than East Africa. Combinations were chosen to optimise PPC (World > 90%, East Africa > 80%) and to 
cover range of allele binding profiles while using an optimal number of epitopes. Making use of a 
small number of epitopes increases the likely occurrence of only positive immunogenicity. By 
choosing epitopes with wide-ranging HLA I and II binding profiles, higher intrinsic and cumulative 
population coverage are guaranteed. Of the five vaccines, three arose by combining CD8+ and CD4+ 
epitopes.  
Antigens with a greater number of epitopes were more likely to produce highly conserved and 
effective epitopes. For the MHC I Class, the highest antigens per epitope were NP_216545.1, 
NP_216249.1 and YP_001283215.1 (Figure 1). These antigens contained eight epitopes which were 
highly conserved and offered effective protection against Tuberculosis. Similarly, NP_216545.1 had 
the second highest epitope count. It contained two highly-conserved epitopes included in the final 
epitope combinations. 
CD4+ epitopes are typically longer and more prevalent, and potentially bind many more alleles than 
CD8+ epitopes. However, CD4+ combinations produced PPC values lower than expected. The 
low PPC values of 81.8% (World) and 68.3% (East Africa) might be raised if more antigens 
were used. Antigens with 15 or more CD4+ epitopes were used for logistic reasons and to 
focus the resulting immune response; setting a lower value – say 10 epitopes – might offer a 
catholic selection without broadening the response unduly.  
Our vaccine does not contain known B-cell epitopes or mimics thereof. Incorporating B cell antigens 
into TB vaccines has been tried in the formulation of the CTA1-DD/ISCOM adjuvant vector. Fusing 
this vector with ESAT-6/Ag85B boosted BCG induced immunity (42). However, a major issue in B cell 
epitope identification is the total lack of accuracy and thus low success rate in their prediction (43, 
44). Given the dominance of cellular immunity in responses to M. tuberculosis, B cell epitopes were 
deprecated in favour of their T cell equivalent.  
Again, we compared the sequences comprising the highest scoring vaccine to the human virtual 
proteome. Even the best match - MLLAVTVSL [overlap: 100%; %identity: 89%; best match: 
EAW77954.1] – is a partial match. It is though that multiple complete matches between an epitope 
and distinct human proteins are necessary for such correspondence to become an issue (45,46,47). 
As the number of complete matches rises, the chance that the native epitope will be presented as 
part of the human “self” peptidome likewise rises, the necessary condition for epitope-mediated 
immune reaction. As more peptidomes are sequenced, the more reliable such predictions will 
become.  
 
 
 5. CONCLUSION 
We used an immunoinformatic protocol to define a vaccine targeting Mycobacterium tuberculosis, 
producing a combined MHC I and MHC II epitope ensemble vaccine that offered 97.4% global 
protection and 92.67% coverage for the East African population. The final seven-epitope 
combination comprised: SRGWSLIKSVRLGNA, KPRIITLTMNPALDI, AAHKGLMNIALAISA, FPAGGSTGSL, 
MLLAVTVSL, QSSFYSDW and KMRCGAPRY; indicate that our putative TB vaccines need both MHC I 
and II epitopes to offer a broad population coverage. In vitro and in vivo testing of our ensemble 
vaccine for protective immune responses and efficacy against Mycobacterium tuberculosis. This and 
other work (22-24) indicates our evolving immunoinformatics design strategy, based on the rigorous 
selection of pre-validated epitopes, is suitable for developing epitope ensemble vaccines across the 
spectrum of key pathogens for human health. 
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FIGURE 1: Prevalence of Epitopes within TB Antigens  
Prevalence of Epitopes within TB Antigens. A: Class I. B. Class II.  
A. The height of each bar represents the number of epitopes present in the named antigen. For 
completeness and accuracy, the number of epitopes also appears above the bar. 18 antigens 
contained 5 or more epitopes.  
 
 B.  The height of each bar represents the number of epitopes present in the named antigen. 
For completeness and accuracy, the number of epitopes also appears above the bar. 14 
antigens contained 15 or more epitopes. 
 
 TABLE 1: Characteristics of Conserved CD8+ Epitopes 
This Table lists the sequences of the conserved CD8+ epitopes identified by the PVS server, as ranked 
in terms of the overall Projected Population Coverage or PPC, given as a percentage, for both the 
world and for East Africa. The PPC is calculated from the prevalence of alleles predicted as binding to 
the given epitope, as listed in the table. The Tuberculosis antigen of origin is also given. 
 
EPITOPE ANTIGEN ID MHC class I BINDING 
PROFILE 
PROJECTED 
POPULATION 
COVERAGE (%) 
WORLD EAST 
AFRICA 
MLLAVTVSL NP_216249.1 HLA-A*32:01, HLA-
A*02:01, HLA-B*08:01, 
HLA-A*02:06 
50.03 28.34 
ALAALGLWLSV NP_216249.1 HLA-A*02:01, HLA-
A*02:03, HLA-A*02:06, 
HLA-A*32:01 
 
44.86 23.04 
FVLPGPSLTV NP_216545.1 HLA-A*02:06, HLA-
A*02:01, HLA-A*02:03 
41.35 20.47 
AAMASASLV Q50906.1 HLA-A*02:01 39.08 20.24 
FPAGGSTGSL NP_216545.1 HLA-B*07:02, HLA-
B*53:01, HLA-B*35:01, 
HLA-B*51:01, HLA-
B*08:01 
38.21 33.60 
HISSGVFLLK NP_216545.1 HLA-A*11:01, HLA-
A*03:01, HLA-A*68:01 
35.75 11.72 
KAGCQTYK YP_001283215.1 HLA-A*30:01, HLA-
A*03:01, HLA-A*11:01 
34.14 20.40 
AVVRFQEAANK POA566.2 HLA-A*11:01, HLA-
A*03:01 
30.92 9.20 
KMRCGAPRY NP_216545.1 HLA-A*30:02, HLA-
B*15:01, HLA-A*30:01, 
HLA-A*03:01 
29.06 32.22 
YQGVQQKW P0A564.2 HLA-A*24:02, HLA-
B*58:01, HLA-B*53:01, 
HLA-B*57:01 
29.00 27.77 
WYYQSGLSI YP_001283215.1 HLA-A*23:01, HLA-
A*24:02 
26.18 17.08 
GVAADYYQR NP_216545.1 HLA-A*31:01, HLA- 25.64 6.47 
A*68:01, HLA-A*11:01 
QSSFYSDW CAA17868.1 HLA-B*58:01, HLA-
B*57:01, HLA-A*01:01, 
HLA-A*30:02 HLA-
A*01:01, HLA-B*15:01, 
HLA-B*15:01 
25.38 34.08 
FSRPGLPVEY CAA17868.1 HLA-A*01:01, HLA-
B*15:01, HLA-B*15:01 
 
24.32 12.36 
MPVGGQSSF CAA17868.1 HLA-B*35:01, HLA-
B*53:01, HLA-B*07:02, 
HLA-B*35:01, HLA-
B*53:01 
 
22.88 23.90 
MAEMKTDAATL NP_218391.1 HLA-B*40:01, HLA-
B*44:02, HLA-B*15:01 
22.88 3.37 
NTPAFEWYY YP_001283215.1 HLA-A*01:01, HLA-
A*26:01 
22.62 13.04 
VSLLTIPF NP_216249.1 HLA-A*32:01, HLA-
A*32:01, HLA-B*57:01, 
HLA-B*57:01, HLA-
A*30:01, HLA-A*30:01, 
HLA-B*58:01, HLA-
B*58:01, HLA-B*15:01, 
HLA-B*15:01 
22.49 26.44 
AEQEQCLDEL NP_216545.1 HLA-B*40:01, HLA-
B*44:02, HLA-B*44:03 
20.88 6.94 
RGAAASAAF NP_216545.1 HLA-B*15:01, HLA-
B*07:02 
20.65 7.37 
LPVEYLQV CAA17868.1 HLA-B*07:02, HLA-
B*07:02, HLA-B*35:01, 
HLA-B*35:01 
 
20.62 10.51 
AVYLLDGLR YP_001283215.1 HLA-A*31:01, HLA-
A*11:01 
20.45 3.87 
FAAAAGTAV NP_216249.1 HLA-A*02:06, HLA-
A*68:02, HLA-B*35:01, 
HLA-A*02:03, HLA-
B*51:01 
 
20.07 22.73 
QSSFYSDWY P31952 HLA-A*01:01, HLA-
A*30:02 
19.55 24.39 
SSFYSDWY CAA17868.1 HLA-B*57:01, HLA- 17.44 26.02 
B*58:01, HLA-B*15:01, 
HLA-A*30:02 
VGQDQYVW NP_216545.1 HLA-B*57:01, HLA-
B*57:01, HLA-B*58:01, 
HLA-B*58:01, HLA-
B*53:01, HLA-B*53:01 
9.70 26.01 
 
 TABLE 2: Characteristics of Conserved CD4+ Epitopes 
This Table lists the sequences of the conserved CD4+ epitopes identified by the PVS server, as ranked 
in terms of the overall Projected Population Coverage or PPC, given as a percentage, for both the 
world and for East Africa. The PPC is calculated from the prevalence of alleles predicted as binding to 
the given epitope, as listed in the table. The Tuberculosis antigen of origin is also given. 
 
EPITOPE ANTIGEN ID MHC class II BINDING 
PROFILE 
PROJECTED 
POPULATION 
COVERAGE 
(%) 
World East 
Africa 
KPRIITLTMNPALDI NP_216545.
1 
HLA-DRB4*01:01, HLA-
DRB1*13:02, HLA-DRB1*04:05, 
HLA-DRB1*09:01, HLA-
DRB1*11:01, HLA-DRB1*04:01, 
HLA-DRB3*02:02, HLA-
DRB1*15:01, HLA-DRB1*08:02, 
HLA-DRB1*07:01, HLA-
DRB1*03:01 
74.13 59.68 
 
 
 
 
 
 
LEAVVMLLAVTVSL
L 
NP_216249.
1 
HLA-DRB1*07:01, HLA-
DRB1*03:01, HLA-DRB1*11:01, 
HLA-DRB1*15:01, HLA-
DRB1*04:01, HLA-DRB1*04:05, 
HLA-DPA1*03:01/DPB1*04:02, 
HLA-DQA1*01:02/DQB1*06:02, 
HLA-DRB1*08:02, HLA-
DRB5*01:01, HLA-DRB1*01:01 
73.40 51.56 
SRGWSLIKSVRLG
NA 
NP_216545.
1 
HLA-DRB1*07:01, HLA-
DRB1*08:02, HLA-DRB1*01:01, 
HLA-DRB3*02:02, HLA-
DRB5*01:01, HLA-DRB1*04:01, 
HLA-DRB1*04:05, HLA-
DRB1*15:01, HLA-DRB1*11:01, 
HLA-DRB1*03:01 
73.40 51.56 
AELMILIATNLLGQN YP_0012826
74.1 
HLA-DRB1*04:01, HLA-
DRB1*01:01, HLA-DRB1*15:01, 
HLA-DRB1*12:01, HLA-
DRB1*04:05, HLA-DRB5*01:01, 
HLA-DPA1*03:01/DPB1*04:02,  
HLA-DRB1*03:01, HLA-
67.91 61.06 
DRB1*11:01, HLA-DRB1*13:02 
AAVVMLLAVTVSLL
TI 
NP_216249.
1 
HLA-DRB1*07:01, HLA-
DRB1*03:01, HLA-DRB1*11:01, 
HLA-DRB1*04:01, HLA-
DRB1*04:05, HLA-
DPA1*03:01/DPB1*04:02,  
HLA-DPA1*01/DPB1*04:01, 
HLA-DRB1*08:02, HLA-
DRB1*15:01, HLA-DRB5*01:01 
66.92 48.73 
ATNFFGINTIPIALF YP_178022.1 HLA-DRB1*04:01, HLA-
DRB1*11:01, HLA-DRB1*04:05, 
HLA-DRB1*08:02, HLA-
DRB1*07:01, HLA-DRB1*13:02, 
HLA-DQA1*01:01/DQB1*05:01, 
HLA-DRB5*01:01, HLA-
DRB1*12:01, HLA-
DPA1*02:01/DPB1*14:01, HLA-
DPA1*02:01/DPB1*01:01, HLA-
DRB3*02:02, HLA-DRB1*03:01 
62.15 64.00 
AALAIAAMASASLV
T 
WP_0039116
90.1 
HLA-DRB1*09:01, HLA-
DQA1*05:01/DQB1*03:01, HLA-
DRB1*01:01, HLA-DRB1*07:01, 
HLA-DQA1*01:02/DQB1*06:02, 
HLA-DRB1*15:01, HLA-
DRB1*04:05, HLA-DRB1*08:02, 
HLA-DRB1*04:01 
60.19 19.90 
TRAILIRVRNASWQ
H 
NP_216249.
1 
HLA-DRB1*08:02, HLA-
DRB1*15:01, HLA-DRB1*11:01, 
HLA-DRB1*04:05, HLA-
DRB1*04:01, HLA-DRB4*01:01, 
HLA-DRB1*03:01, HLA-
DRB1*13:02 
59.44 51.56 
AGLMVAAASPYVA
WM 
YP_0012826
74.1 
HLA-DRB3*01:01, HLA-
DRB1*08:02, HLA-DRB1*09:01, 
HLA-DRB1*12:01, HLA-
DRB1*15:01, HLA-DRB1*03:01, 
HLA-DRB3*02:02, HLA-
DRB1*01:01 
53.29 29.27 
RDVLAVVSKASGL
VI 
P09621.3 HLA-DRB1*08:02, HLA-
DRB1*11:01, HLA-DRB1*07:01, 
HLA-DRB5*01:01, HLA-
DRB1*15:01, HLA-DRB1*13:02 
49.93 44.94 
AAHKGLMNIALAIS
A 
P15712.1 HLA-DRB1*09:01, HLA-
DRB1*11:01, HLA-DRB1*08:02, 
HLA-DQA1*01:02/DQB1*06:02, 
HLA-DRB1*12:01, HLA-
DRB1*03:01, HLA-DRB1*04:01 
47.05 48.30 
PAFEWYYQSGLSIV
M 
YP_0012832
15.1   
HLA-DRB1*07:01, HLA-
DPA1*02:01/DPB1*01:01, HLA-
DRB1*11:01, HLA-DRB5*01:01, 
HLA-DPA1*02:01/DPB1*14:01, 
HLA-DRB1*04:01, HLA-
DQA1*01:01/DQB1*05:01, HLA-
DRB1*09:01, HLA-
DPA1*01:03/DPB1*02:01, HLA-
DPA1*01/DPB1*04:01 
42.27 36.80 
AFAGIEAAASAIQG
N 
P0A564.2 HLA-DRB1*13:02, HLA-
DRB1*07:01, HLA-
DPA1*03:01/DPB1*04:02, HLA-
DRB1*03:01, HLA-DRB3*01:01, 
HLA-DPA1*02:01/DPB1*01:01, 
HLA-DPA1*02:01/DPB1*14:01 
39.68 33.09 
AFEWLQVPSPSMG
RD 
POA4V2.1 HLA-DRB1*04:01, HLA-
DRB1*09:01, HLA-DRB1*04:05, 
HLA-DRB1*01:01, HLA-
DRB1*11:01 
39.02 36.16 
AVYLLDGLRAQSG
LS 
P0C5B9.1 HLA-DRB1*11:01, HLA-
DRB3*01:01, HLA-DRB1*08:02, 
HLA-DRB1*04:01, HLA-
DRB1*03:01 
38.72 38.22 
CQTYKWETFLTSE
LP 
POA4V2.1 HLA-DPA1*01/DPB1*04:01, 
HLA-DPA1*02:01/DPB1*05:01, 
HLA-DPA1*02:01/DPB1*01:01, 
HLA-DPA1*02:01/DPB1*14:01, 
HLA-DPA1*03:01/DPB1*04:02, 
HLA-DRB1*07:01, HLA-
DQA1*01:02/DQB1*06:02, HLA-
DRB1*08:02, HLA-DRB1*03:01 
36.16 21.85 
AATAQTLQAFLHW
AI 
P15712.1 HLA-DRB1*15:01, HLA-
DRB1*07:01 
34.78 9.37 
EEYLILEDKILVQAN P09621.3 HLA-DRB1*03:01, HLA-
DPA1*03:01/DPB1*04:02, HLA-
DRB1*04:01, HLA-DRB4*01:01, 
HLA-DPA1*02:01/DPB1*14:01, 
HLA-DRB5*01:01 
27.97 13.51 
AGVQYSRADVVRF
QE 
NP_218391.
1 
HLA-DRB3*02:02, HLA-
DRB1*13:02, HLA-DRB1*07:01 
24.27 21.15 
AAVVRFQEAANKQ
KQ 
NP_218391.
1 
HLA-DRB5*01:01, HLA-
DRB1*08:02, HLA-DRB1*04:01, 
HLA-DRB1*11:01, 
23.19 26.73 
DQVHFQPLPPAVV
KL 
P15712.1 HLA-DRB1*01:01, HLA-
DRB1*09:01, HLA-DRB1*12:01 
21.60 16.64 
AAWGGWNFAGIEA
AA 
P0A564.2 HLA-DRB1*11:01, HLA-
DRB1*04:05, HLA-DRB1*09:01 
19.34 32.92 
AAVLTDASATKDG
SH 
P0A5J0.1 HLA-DRB1*11:01, HLA-
DRB3*01:01 
10.54 26.73 
CVAYIGISFLDQAS
Q 
P15712.1 HLA-DPA1*01:03/DPB1*02:01, 
HLA-DQA1*01:01/DQB1*05:01, 
HLA-DPA1*01/DPB1*04:01, 
HLA-DPA1*02:01/DPB1*01:01, 
HLA-DPA1*02:01/DPB1*14:01, 
HLA-DQA1*05:01/DQB1*02:01, 
HLA-DRB1*11:01, HLA-
DRB4*01:01, HLA-
DPA1*03:01/DPB1*04:02 
10.54 26.73 
 
 
 
 TABLE 3: Characteristics of Epitope combinations 
The optimal combinations of conserved CD8+ and CD4+ epitopes are listed below. This Table lists the 
sequences of the conserved CD8+ and CD4+ epitopes ranked on their overall Projected Population 
Coverage or PPC, given as a percentage, for both the world and for East Africa. The PPC is calculated 
from the prevalence of alleles predicted as binding to the given epitope, see tables 1 and 2.  
 
EPITOPE COMBINATION PPC (%) 
WORLD EAST 
AFRICA 
QSSFYSDW, ALAALGLWLSV, MLLAVTVSL, 
AEQEQCLDEL, FPAGGSTGSL, HISSGVFLLK, 
KMRCGAPRY, WYYQSGLSI, NTPAFEWYY 
97.76 86.14 
SRGWSLIKSVRLGNA, KPRIITLTMNPALDI, 
AAHKGLMNIALAISA, FPAGGSTGSL, 
MLLAVTVSL, QSSFYSDW, KMRCGAPRY 
97.39 92.67 
QSSFYSDW, MLLAVTVSL, AEQEQCLDEL, 
FPAGGSTGSL, HISSGVFLLK, KMRCGAPRY, 
WYYQSGLSI 
97.11 85.63 
SRGWSLIKSVRLGNA, KPRIITLTMNPALDI, 
AAHKGLMNIALAISA, FPAGGSTGSL, 
MLLAVTVSL, QSSFYSDW 
96.09 88.27 
SRGWSLIKSVRLGNA, KPRIITLTMNPALDI, 
AAHKGLMNIALAISA, FPAGGSTGSL, 
MLLAVTVSL 
93.72 83.80 
 
 
 
